In 2019, the number of deaths directly attributed to antimicrobial resistant (AMR) infection were the same, if not greater than those directly attributed to HIV/AIDs or malaria, causing AMR to be termed by some as the 'silent pandemic'. By 2050, it has been predicted that a greater number of people will die from the primary effects of AMR than currently die from cancer, unless significant interventions are implemented. Although the ongoing rise in AMR has traditionally been attributed to the misuse of antibiotics, there is evidence that the impacts of the COVID-19 pandemic could be a further contributing factor. Although, clinical resistance has now been identified to every antibiotic commonly prescribed, including colistin, 12 new antibiotics were approved for clinical use between 2017-2021, with a further 45 in development. Of these, 60 % target WHO priority pathogens. Encouragingly, these numbers are predicted to rise through the launch of new initiatives to ensure the financial viability of the antibiotic development pipeline, previously absent. However, these novel antibiotics still do not fulfil the ever increasing global need. The majority of AMR research is focused on inhibiting the growth of pathogenic planktonic cells, unintentionally ignoring biofilms, which is concerning when considering the significant economic impact that chronic and reoccurring biofilm based infections place on the global healthcare system. This is estimated at $281 billion (2017) for the treatment of wounds alone. When considered alongside the impact of biofilms within the food processing, marine, water supply and agricultural industries, the global economic impact associated with these microbial systems is estimated in the $trillions annually. Encasing microbes within a biofilm is known to reduce antibiotic efficacy by up to three orders of magnitude, while the polymicrobial nature of heterogenous biofilms is known to further drive AMR through both microbial synergy and plasmid exchange processes. The field of supramolecular chemistry has contributed a number of innovations towards the development of novel antimicrobial technologies, including synthetic ion transporters (ion carriers, ion channels ), polymeric materials and drug delivery vehicles. However, relatively few examples focus on the development of antibiofilm agents against heterogenous or homogenous biofilms. These examples include those by Nagarajan et al. who developed gluconamide based supramolecular gels, which act as antibiofilm agents against a range of Gram-positive and Gram-negative bacteria, including examples which appear on the 2024 WHO bacterial Priority Pathogen list, for which novel antimicrobial strategies are urgently needed (e.g. Staphylococcus aureus, Listeria monocyogenes, Salmonella enterica and Pseudomonas aeruginosa). In addition, Wang et al. have used eco-friendly β-cyclodextrin/stilbene-integrated supramolecular materials as antibiofilm agents against Xanthomonas oryzae pv. oryzae, which causes bacterial blight in rice. Finally, Zhou et al. have developed a series of supramolecular tripeptide based amphiphiles, which self-assembled into 1-D assemblies that could be reversibly disassembled due to environmental stimuli, such as light and competitive host-guest interactions, enabling control of antibiofilm activities against Gram-positive S. aureus and Gram-negative P. aeruginosa. Concerningly, even fewer examples (such as that provided by Yang and Hendrick et al.) exist where supramolecular innovations have been developed against biofilms containing fungal pathogens, specifically those detailed within the WHO priority fungal pathogens list, e.g. Candida albicans -which is one of the four fungal species to be considered a 'critical threat' to public health. Within the scope of our own work, we have developed a class of supramolecular self-associating amphiphiles (SSAs), which exhibit drug-like properties and have been shown to act as both antimicrobial and antibiofilm agents, against WHO priority pathogens, both bacterial and fungal. SSAs, such as the examples detailed in Figure , are a group of amphiphilic salts and related compounds, the majority of which contain a hydrophobic functionality, linked by a hydrogen bond donor/acceptor group, through an alkyl spacer, to an anionic moiety, that is charged balanced through the presence of a separate counter cation, typically tetrabutylammonium (TBA). These SSAs have been shown to adopt low order anionic dimeric species in polar organic solvent, spherical aggregates with a hydrodynamic diameter (dH) between ~ 100-500 nm in 1:19 EtOH:H2O solutions and hydrogels upon the addition of inorganic salts such as NaCl.